190
Participants
Start Date
November 29, 2016
Primary Completion Date
May 11, 2022
Study Completion Date
May 11, 2022
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Relatlimab
Specified dose on specified days
BMS-986205
Specified dose on specified days
Rucaparib
Specified dose on specified days
Local Institution, Randwick
Local Institution - 0035, Westmead
Local Institution - 0033, Heidelberg
Local Institution - 0041, Chur
Local Institution - 0042, Zurich
Local Institution - 0007, New York
UPMC, Pittsburgh
Local Institution - 0005, Philadelphia
Local Institution - 0036, Washington D.C.
IRCCS Istituto Nazionale Tumori Milano, Milan
Local Institution - 0014, Milan
Local Institution - 0006, Baltimore
Local Institution - 0038, Jacksonville
UF Health Medical Oncology - Davis Cancer Pavilion, Gainesville
Local Institution, Ramat Gan
Local Institution - 0017, Rochester
Local Institution - 0003, St Louis
Local Institution, Tel Aviv
Local Institution - 0039, Heidelberg
University Of Colorado, Aurora
Mayo Clinic Arizona, Phoenix
Local Institution - 0002, Portland
Local Institution - 0004, Seattle
Local Institution - 0050, Singapore
Local Institution - 0020, Duarte
Local Institution - 0032, New Haven
Local Institution - 0001, Hackensack
Local Institution, Edmonton
Local Institution, Vancouver
Local Institution, Ottawa
Local Institution - 0025, Toronto
Local Institution - 0021, Toronto
Local Institution - 0043, Leipzig
Local Institution, Amsterdam
Local Institution, Utrecht
Lead Sponsor
Collaborators (1)
Clovis Oncology, Inc.
INDUSTRY
Bristol-Myers Squibb
INDUSTRY